Concepedia

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Åke Berglund, Anders Ullén, Alla Lisyanskaya, Hans Hagberg, Bengt Tholander, Rolf Lewensohn, Peter Nygren, Jack Spira, Johan Harmenberg, Markus Jerling,

Investigational New Drugs · 2015 · 30 citations · 20 references

DOI

Concepts

References

20

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

Renata Pasqualini, Erkki Koivunen, Renate Kain et al. · PubMed · 2000 · 867 citations

, , +16

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Marta Chesi, Geoffrey M. Matthews, Victoria M. Garbitt et al. · Blood · 2012 · 209 citations

, , +11

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

T. Facon · Blood · 2005 · 179 citations · Full text

, , +12

Clinical Significance of Aminopeptidase N in Non–Small Cell Lung Cancer

Takahiro Tokuhara, Noboru Hattori, Hisao Ishida et al. · Clinical Cancer Research · 2006 · 110 citations · Full text

, , +17

The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis

Shripad V. Bhagwat, Nenad Petrović, Yasuhiro Okamoto et al. · Blood · 2003 · 106 citations · Full text

, , +13